Cencora, Inc. (COR)

Cencora is the second-largest pharmaceutical distributor in the United States and a major supplier to hospitals, pharmacies, and healthcare providers across North America and internationally. It stands in the middle of the healthcare supply chain — between pharmaceutical manufacturers who produce drugs and the retailers and clinics that dispense them to patients. Cencora’s business is to move those products efficiently, reduce costs where possible, and provide the systems and data that allow its customers to operate their pharmacies and medical supply chains effectively. For most patients, the company is invisible; its name does not appear on packaging or receipts. Yet the business is essential infrastructure, and its combination of scale, operational efficiency, and data capabilities gives it durable advantages.

The Consolidation That Created Cencora

The pharmaceutical distribution industry has consolidated dramatically over the past two decades. Cencora itself is the product of a 2001 merger between AmeriSource Health and Bergen Brunswig, two major regional distributors. That combination, followed by the 2018 acquisition of PharMerica’s distribution operations and continued organic growth, has positioned Cencora as a near-duopoly player with one comparable competitor in the United States.

This consolidation reflects genuine economics. Larger distributors can negotiate better prices from manufacturers, operate larger warehouse networks that reduce delivery costs, invest more heavily in automation and technology, and spread overhead across more volume. A small distributor cannot compete on price against a megadistributor’s costs and so is forced to accept lower margins or exit the market. The result is an industry where two companies now control roughly two-thirds of all pharmaceutical wholesale in the United States — a concentration that has drawn regulatory attention but that reflects the capital intensity and scale economies of the business.

How Cencora Makes Money

Cencora’s primary revenue comes from the spread between the wholesale price it pays for drugs from manufacturers and the price it charges to pharmacies and hospitals. That spread — typically 1 to 3 percent of the product’s sale price — is thin, but the company moves enormous volume. A busy pharmacy might purchase from Cencora multiple times a week; a hospital system with hundreds of locations orders on an even larger scale. That volume multiplied by the thin margin generates substantial revenue and — given the variable-cost nature of distribution — good operating leverage.

The company also earns significant revenue from specialty pharmaceutical distribution, where the margins are higher. Specialty drugs — expensive, often complex-to-administer medicines for conditions like cancer, autoimmune diseases, or hemophilia — cannot be handled like ordinary pills. They require careful storage, sometimes refrigeration, specialized handling and delivery, patient education, and adherence support. Cencora operates a specialty pharmacy business that dispenses these drugs directly to patients or healthcare providers, capturing higher margins for the additional service.

A third and growing revenue stream comes from data, analytics, and information services provided to pharmacies and healthcare systems. Cencora operates platforms that allow pharmacies to manage inventory, track patient adherence, identify cost-saving opportunities, and comply with regulations. These services command recurring fees and are not purely dependent on transaction volume, providing some margin stability.

Scale, Automation, and Inventory Management

Operating a national or international pharmaceutical supply chain requires infrastructure that only the largest players can afford. Cencora operates a network of large, automated distribution centers across the United States and in several international markets. These facilities use robotics, conveyor systems, and sophisticated software to sort, pack, and ship thousands of prescriptions daily. The automation reduces labor costs, improves accuracy, and speeds delivery times.

Inventory management is critical. A pharmacy might need a particular drug within hours; manufacturers produce in batches; and some drugs are subject to demand volatility or scarcity. Cencora’s role includes holding inventory distributed across its network so it can fulfill emergency orders quickly and allow pharmacies to operate with less inventory on their own shelves. This inventory management is both a service and a source of risk — if a drug is recalled or demand collapses, Cencora absorbs the loss.

The Specialty and International Expansion

Cencora has grown internationally through acquisitions and organic expansion. It operates significant businesses in Canada, Mexico, and Europe, providing the same distribution and specialized services to pharmacies and healthcare providers outside the United States. These operations provide revenue diversification and hedge against US regulatory or competitive developments.

Specialty pharmacy has been a particular focus. As the industry has shifted toward more expensive, complex medications — particularly biopharmaceuticals and oncology drugs — the margins in specialty distribution have been stronger than in commodity generic distribution. Cencora has invested in patient services, clinical support, and direct-to-patient dispensing to build scale in specialty, acquiring platform companies and building internal capabilities.

Competitive Pressures and Margin Compression

The pharmaceutical distribution industry faces relentless margin pressure. Drug manufacturers have worked to bypass traditional distributors, negotiating directly with large hospital systems or using alternative channels. The rise of mail-order and online pharmacy has created new competitive dynamics. And large pharmacy chains with their own distribution arms sometimes compete directly with Cencora for supplying independent pharmacies.

Generic drug pricing has also compressed. When a brand-name drug goes off patent and multiple manufacturers produce generic versions, prices fall sharply. Distributors capture less absolute margin on each unit, though they may move more volume at lower prices. This dynamic puts continuous pressure on margins unless Cencora can grow volume faster than margin erodes or shift customers toward higher-margin specialty and services.

Manufacturer consolidation also affects pricing power. Larger pharmaceutical companies have more leverage in negotiations with distributors, and some have experimented with direct distribution models to capture margin that would otherwise go to wholesalers.

Regulatory Environment and Opioid Litigation

The pharmaceutical distribution industry faces ongoing regulatory and litigation risk tied to the opioid epidemic. Distributors are required to maintain anti-diversion controls — systems to detect and prevent the shipment of opioids to pharmacies or facilities that are diverting them to illegal markets. Cencora and its competitors have faced numerous lawsuits from states and municipalities claiming distributors failed in this duty. These cases have resulted in substantial settlements, and the company carries litigation reserves and insurance to cover ongoing exposure.

Regulatory changes could also require distributors to invest in new compliance systems or implement new screening protocols that increase operating costs.

How to Research Cencora

Study begins with the company’s annual 10-K filing (SEC CIK 0001140859), which breaks revenue by segment (U.S. pharmaceutical distribution, specialty pharmacy, and international), outlines the competitive landscape, and details risks. Quarterly earnings reports reveal trends in volume, margin pressure, and the health of specialty and international growth. Pay particular attention to trends in generic versus brand-drug mix, as that affects margins; commentary on customer consolidation (pharmacy mergers and health-system acquisitions); and pricing discussions with manufacturers and large customers.

Key metrics include gross margin (the spread between what Cencora pays and what it charges), operating margin (how much of each revenue dollar becomes operating profit after all operating expenses), return on capital, and growth in specialty pharmacy as a percentage of total revenue. Watch for any commentary on technology investment, new service offerings, or acquisitions that signal areas of strategic focus.